DV
Dividend Vision

SPRC Stock — Scisparc Ltd

Scisparc Ltd (SPRC)

Updated October 16, 2026.

SPRC is a Stock. Total return is -100.0% over the past 5.1 years, 181.0 points behind SPY at 81.0%.

SciSparc Ltd. is a clinical-stage pharmaceutical company developing cannabinoid-based drug therapies, including programs targeting Tourette syndrome, Alzheimer's disease with agitation, autism spectrum disorder, and chronic pain, along with hemp seed oil-based consumer products. The company does not currently have an established distribution schedule. This security may appeal to investors seeking exposure to early-stage pharmaceutical development and cannabis-derived therapeutics, though clinical-stage companies carry substantial development and regulatory risks with no guarantee of commercialization success.

SPRC performance versus SPY

Price and return data through 2026-10-16.

Total return is -100.0% over the past 5.1 years, 181.0 points behind SPY at 81.0%. Over the past year its total return — price change plus distributions reinvested — is -95.2%. Its deepest 1-year drawdown was 95.6%.

WindowTotal returnCAGR
1M-63.7%—
3M-68.3%—
6M-59.9%—
YTD-86.1%—
1Y-95.2%—
2Y CAGR—-79.90%
3Y CAGR—-85.30%
5Y CAGR—-85.60%
Since inception (5.1 years)-100.0%-84.20%

SPRC key facts

Asset type
Stock
Asset class
Equity
Distribution frequency
None
Last close
$1.70 (as of 2026-10-16)
Market cap
$987,654
Average volume
379222.0
Beta
2.549
Payout ratio
0.0%
P/E ratio
0.01
EPS
$228.08

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

SPRC risks and drawbacks

Total return has trailed SPY over the available window. The deepest 1-year drawdown on record here is 95.6%.

Who may consider SPRC — and who may not

It is a weaker fit for investors who need monthly cash flow (SPRC does not currently distribute); investors whose main goal is matching SPY total return. This is educational context, not a recommendation to buy or sell.

More on SPRC

Tagged: Healthcare.

Frequently asked questions

Does SPRC pay monthly?

No. SPRC does not currently distribute.

When does SPRC pay a dividend?

SPRC does not currently distribute.

How has SPRC performed?

Total return is -100.0% over the past 5.1 years, 181.0 points behind SPY at 81.0%. Over the past year its total return — price change plus distributions reinvested — is -95.2%. Its deepest 1-year drawdown was 95.6%.

DividendVision analysis is generated from public SEC filing data and may not capture every change. Review the original filing for complete information.